News Pharma Industry

lupin: Lupin’s test: Can the diversification into a tough diagnostics market break its new-ventures jinx?

Rajeev Sibal (left), president of India formulation business head, and Ravindra Kumar, head of Lupin Diagnostic.


The pharma company has launched this new venture, sniffing opportunity in the pandemic’s wake. But competition in this fragmented sector is also at an all-time high. Moreover, some of the company’s strategic bets from the past haven’t yielded results, and its returns have been falling, too. What are the chances that the latest diversification will fly amid these headwinds?

Medical diagnostics in the times of a pandemic is a lucrative business. People who are ill get tested, as do people with chronic conditions. Even healthy individuals get tested, as part of travel clearances or as a precaution. Leaving aside April to June of 2020, the pandemic has not only brought in volumes, but also improved the profitability of major diagnostics companies. Riding this wave, pharma company Lupin announced its foray into

  • SAVE

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Great New Year Sale


On ET Prime & stay ahead of the rest in 2022

Get Offer

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Source link